{
    "interactions": [
        {
            "id": "ddi_001",
            "drug_pair": ["warfarin", "aspirin"],
            "severity": "high",
            "mechanism": "Additive anticoagulant effect - increased bleeding risk",
            "clinical_effect": "Major bleeding, hemorrhage",
            "penalty": -10,
            "management": "Avoid combination or use with extreme caution, monitor INR closely",
            "evidence_level": "High",
            "source": "FDA Drug Interaction Label, DrugBank"
        },
        {
            "id": "ddi_002",
            "drug_pair": ["warfarin", "ibuprofen"],
            "severity": "high",
            "mechanism": "NSAIDs inhibit platelet function and may cause GI bleeding",
            "clinical_effect": "Increased bleeding risk, GI hemorrhage",
            "penalty": -10,
            "management": "Use alternative analgesic (acetaminophen), monitor INR",
            "evidence_level": "High",
            "source": "FDA, DDInter"
        },
        {
            "id": "ddi_003",
            "drug_pair": ["aspirin", "ibuprofen"],
            "severity": "medium",
            "mechanism": "Ibuprofen may interfere with aspirin's cardioprotective effects",
            "clinical_effect": "Reduced antiplatelet efficacy, increased GI bleeding",
            "penalty": -5,
            "management": "Take aspirin 2+ hours before ibuprofen",
            "evidence_level": "Medium",
            "source": "FDA Advisory, DrugBank"
        },
        {
            "id": "ddi_004",
            "drug_pair": ["lisinopril", "ibuprofen"],
            "severity": "medium",
            "mechanism": "NSAIDs reduce renal prostaglandins, antagonizing ACE inhibitor effect",
            "clinical_effect": "Reduced blood pressure control, acute kidney injury",
            "penalty": -5,
            "management": "Monitor BP and renal function, use lowest NSAID dose",
            "evidence_level": "Medium",
            "source": "UpToDate, DrugBank"
        },
        {
            "id": "ddi_005",
            "drug_pair": ["atorvastatin", "warfarin"],
            "severity": "medium",
            "mechanism": "Statins may potentiate warfarin via CYP450 interactions",
            "clinical_effect": "Increased INR, bleeding risk",
            "penalty": -5,
            "management": "Monitor INR when initiating/changing statin dose",
            "evidence_level": "Medium",
            "source": "FDA Label, DrugBank DB01076"
        },
        {
            "id": "ddi_013",
            "drug_pair": ["rivaroxaban", "aspirin"],
            "severity": "high",
            "mechanism": "Additive anticoagulant + antiplatelet effects",
            "clinical_effect": "Major bleeding, hemorrhage",
            "penalty": -10,
            "management": "Avoid combination except under specific protocols (e.g., ACS), monitor for bleeding",
            "evidence_level": "High",
            "source": "FDA Label DB06228, DDInter"
        },
        {
            "id": "ddi_014",
            "drug_pair": ["apixaban", "clopidogrel"],
            "severity": "high",
            "mechanism": "Dual anticoagulant + antiplatelet pathway",
            "clinical_effect": "Major bleeding",
            "penalty": -10,
            "management": "Avoid unless clear indication (e.g., dual pathway inhibition post-stent)",
            "evidence_level": "High",
            "source": "FDA Label DB06605"
        },
        {
            "id": "ddi_015",
            "drug_pair": ["dabigatran", "aspirin"],
            "severity": "high",
            "mechanism": "Additive antithrombotic effects",
            "clinical_effect": "Increased bleeding risk",
            "penalty": -10,
            "management": "Use only when benefit outweighs risk, dose reduction may be needed",
            "evidence_level": "High",
            "source": "FDA Label DB06695"
        },
        {
            "id": "ddi_016",
            "drug_pair": ["metoprolol", "digoxin"],
            "severity": "high",
            "mechanism": "Additive effects on AV node conduction",
            "clinical_effect": "Bradycardia, heart block, syncope",
            "penalty": -10,
            "management": "Monitor HR and ECG, dose adjustment often needed",
            "evidence_level": "High",
            "source": "FDA, DrugBank DB00264"
        },
        {
            "id": "ddi_017",
            "drug_pair": ["carvedilol", "digoxin"],
            "severity": "high",
            "mechanism": "Beta-blocker + cardiac glycoside on AV node",
            "clinical_effect": "Severe bradycardia, AV block",
            "penalty": -10,
            "management": "Reduce doses, frequent ECG monitoring",
            "evidence_level": "High",
            "source": "FDA Label, DrugBank"
        },
        {
            "id": "ddi_018",
            "drug_pair": ["spironolactone", "lisinopril"],
            "severity": "high",
            "mechanism": "Both drugs increase potassium retention",
            "clinical_effect": "Life-threatening hyperkalemia, arrhythmias",
            "penalty": -10,
            "management": "Frequent potassium monitoring, dose reduction, contraindicated in severe renal impairment",
            "evidence_level": "High",
            "source": "FDA Black Box Warning, UpToDate"
        },
        {
            "id": "ddi_019",
            "drug_pair": ["spironolactone", "enalapril"],
            "severity": "high",
            "mechanism": "Dual potassium-sparing effect",
            "clinical_effect": "Hyperkalemia",
            "penalty": -10,
            "management": "Monitor K+ closely, avoid in CKD stage 4+",
            "evidence_level": "High",
            "source": "Clinical guidelines, FDA"
        },
        {
            "id": "ddi_020",
            "drug_pair": ["spironolactone", "losartan"],
            "severity": "high",
            "mechanism": "ARB + aldosterone antagonist",
            "clinical_effect": "Severe hyperkalemia",
            "penalty": -10,
            "management": "Use only with renal function monitoring, check K+ weekly initially",
            "evidence_level": "High",
            "source": "FDA, DrugBank"
        },
        {
            "id": "ddi_021",
            "drug_pair": ["warfarin", "rivaroxaban"],
            "severity": "high",
            "mechanism": "Dual anticoagulation",
            "clinical_effect": "Extreme bleeding risk",
            "penalty": -12,
            "management": "Absolutely avoid unless transitioning between agents under supervision",
            "evidence_level": "High",
            "source": "FDA Contraindication"
        },
        {
            "id": "ddi_022",
            "drug_pair": ["warfarin", "apixaban"],
            "severity": "high",
            "mechanism": "Dual anticoagulation",
            "clinical_effect": "Life-threatening hemorrhage",
            "penalty": -12,
            "management": "Contraindicated except during agent transition",
            "evidence_level": "High",
            "source": "FDA Contraindication"
        },
        {
            "id": "ddi_023",
            "drug_pair": ["rivaroxaban", "apixaban"],
            "severity": "high",
            "mechanism": "Dual DOAC therapy",
            "clinical_effect": "Severe bleeding",
            "penalty": -12,
            "management": "Absolutely contraindicated",
            "evidence_level": "High",
            "source": "FDA"
        },
        {
            "id": "ddi_024",
            "drug_pair": ["furosemide", "digoxin"],
            "severity": "medium",
            "mechanism": "Loop diuretic causes hypokalemia, increasing digoxin toxicity risk",
            "clinical_effect": "Digoxin toxicity, arrhythmias",
            "penalty": -5,
            "management": "Monitor K+, Mg2+, digoxin levels; supplement electrolytes",
            "evidence_level": "High",
            "source": "FDA, Clinical pharmacology"
        },
        {
            "id": "ddi_025",
            "drug_pair": ["hydrochlorothiazide", "digoxin"],
            "severity": "medium",
            "mechanism": "Thiazide-induced hypokalemia",
            "clinical_effect": "Increased digoxin toxicity",
            "penalty": -5,
            "management": "Potassium supplementation, monitor digoxin level",
            "evidence_level": "High",
            "source": "FDA Label"
        },
        {
            "id": "ddi_026",
            "drug_pair": ["metoprolol", "amlodipine"],
            "severity": "medium",
            "mechanism": "Additive negative inotropic and chronotropic effects",
            "clinical_effect": "Bradycardia, hypotension, heart failure exacerbation",
            "penalty": -5,
            "management": "Monitor BP and HR, titrate doses cautiously",
            "evidence_level": "Medium",
            "source": "DrugBank, Clinical practice"
        },
        {
            "id": "ddi_027",
            "drug_pair": ["atenolol", "amlodipine"],
            "severity": "medium",
            "mechanism": "Synergistic BP lowering",
            "clinical_effect": "Hypotension, dizziness",
            "penalty": -5,
            "management": "Start with low doses, monitor BP",
            "evidence_level": "Medium",
            "source": "DrugBank"
        },
        {
            "id": "ddi_028",
            "drug_pair": ["furosemide", "lisinopril"],
            "severity": "medium",
            "mechanism": "Diuretic-induced hypotension + ACE inhibitor",
            "clinical_effect": "First-dose hypotension, acute kidney injury",
            "penalty": -5,
            "management": "Start ACE inhibitor at low dose, monitor BP and SCr",
            "evidence_level": "Medium",
            "source": "Clinical guidelines"
        },
        {
            "id": "ddi_029",
            "drug_pair": ["furosemide", "enalapril"],
            "severity": "medium",
            "mechanism": "Volume depletion + ACE inhibitor",
            "clinical_effect": "Hypotension, renal impairment",
            "penalty": -5,
            "management": "Ensure adequate hydration, dose adjust",
            "evidence_level": "Medium",
            "source": "FDA, UpToDate"
        },
        {
            "id": "ddi_030",
            "drug_pair": ["hydrochlorothiazide", "losartan"],
            "severity": "low",
            "mechanism": "Often combined intentionally (HCTZ+ARB combination products)",
            "clinical_effect": "Additive antihypertensive effect (desired)",
            "penalty": 0,
            "management": "Commonly co-prescribed, monitor BP and electrolytes",
            "evidence_level": "None",
            "source": "Clinical practice"
        },
        {
            "id": "ddi_031",
            "drug_pair": ["metoprolol", "metformin"],
            "severity": "medium",
            "mechanism": "Beta-blockers may mask hypoglycemia symptoms",
            "clinical_effect": "Delayed recognition of hypoglycemia",
            "penalty": -5,
            "management": "Patient education on hypoglycemia, frequent glucose monitoring",
            "evidence_level": "Medium",
            "source": "FDA Label, Clinical guidelines"
        },
        {
            "id": "ddi_032",
            "drug_pair": ["atenolol", "metformin"],
            "severity": "medium",
            "mechanism": "Hypoglycemia masking",
            "clinical_effect": "Blunted hypoglycemic awareness",
            "penalty": -5,
            "management": "CGM if available, educate on non-adrenergic symptoms",
            "evidence_level": "Medium",
            "source": "ADA guidelines"
        },
        {
            "id": "ddi_033",
            "drug_pair": ["clopidogrel", "aspirin"],
            "severity": "medium",
            "mechanism": "Dual antiplatelet therapy (DAPT)",
            "clinical_effect": "Increased bleeding risk (acceptable in ACS, post-stent)",
            "penalty": -3,
            "management": "Use only with clear indication, limited duration (6-12 months typically)",
            "evidence_level": "High",
            "source": "ACC/AHA Guidelines"
        },
        {
            "id": "ddi_034",
            "drug_pair": ["clopidogrel", "ibuprofen"],
            "severity": "medium",
            "mechanism": "Antiplatelet + NSAID",
            "clinical_effect": "GI bleeding, increased hemorrhage risk",
            "penalty": -5,
            "management": "Add PPI, use acetaminophen instead",
            "evidence_level": "Medium",
            "source": "FDA, Gastroenterology guidelines"
        },
        {
            "id": "ddi_035",
            "drug_pair": ["losartan", "ibuprofen"],
            "severity": "medium",
            "mechanism": "NSAIDs antagonize ARB antihypertensive effect",
            "clinical_effect": "Reduced BP control, AKI risk",
            "penalty": -5,
            "management": "Limit NSAID use, monitor BP and renal function",
            "evidence_level": "Medium",
            "source": "Hypertension guidelines"
        },
        {
            "id": "ddi_036",
            "drug_pair": ["valsartan", "ibuprofen"],
            "severity": "medium",
            "mechanism": "NSAID + ARB interaction",
            "clinical_effect": "Renal impairment, reduced efficacy",
            "penalty": -5,
            "management": "Alternative analgesic preferred",
            "evidence_level": "Medium",
            "source": "DrugBank, FDA"
        },
        {
            "id": "ddi_037",
            "drug_pair": ["enalapril", "ibuprofen"],
            "severity": "medium",
            "mechanism": "NSAID + ACE inhibitor",
            "clinical_effect": "AKI, hyperkalemia, reduced BP control",
            "penalty": -5,
            "management": "Avoid NSAIDs, monitor renal function",
            "evidence_level": "Medium",
            "source": "Nephrology guidelines"
        },
        {
            "id": "ddi_038",
            "drug_pair": ["ramipril", "ibuprofen"],
            "severity": "medium",
            "mechanism": "NSAID antagonism of ACE inhibitor",
            "clinical_effect": "Acute kidney injury, hyperkalemia",
            "penalty": -5,
            "management": "Use acetaminophen, check SCr and K+",
            "evidence_level": "Medium",
            "source": "FDA, Clinical practice"
        },
        {
            "id": "ddi_039",
            "drug_pair": ["rivaroxaban", "ibuprofen"],
            "severity": "medium",
            "mechanism": "DOAC + NSAID",
            "clinical_effect": "Increased bleeding risk",
            "penalty": -5,
            "management": "Minimize NSAID use, monitor for bleeding",
            "evidence_level": "Medium",
            "source": "FDA Label DB06228"
        },
        {
            "id": "ddi_040",
            "drug_pair": ["apixaban", "ibuprofen"],
            "severity": "medium",
            "mechanism": "Anticoagulant + antiplatelet effect of NSAID",
            "clinical_effect": "Bleeding",
            "penalty": -5,
            "management": "Use alternative analgesic",
            "evidence_level": "Medium",
            "source": "FDA Label DB06605"
        },
        {
            "id": "ddi_041",
            "drug_pair": ["metoprolol", "atenolol"],
            "severity": "low",
            "mechanism": "Duplicate therapy (both beta-blockers)",
            "clinical_effect": "Excessive beta-blockade, no therapeutic benefit",
            "penalty": -3,
            "management": "Use only one beta-blocker",
            "evidence_level": "High",
            "source": "Clinical practice"
        },
        {
            "id": "ddi_042",
            "drug_pair": ["lisinopril", "enalapril"],
            "severity": "low",
            "mechanism": "Duplicate ACE inhibitor therapy",
            "clinical_effect": "No additional benefit, increased adverse effects",
            "penalty": -3,
            "management": "Choose one ACE inhibitor",
            "evidence_level": "High",
            "source": "Clinical guidelines"
        },
        {
            "id": "ddi_043",
            "drug_pair": ["losartan", "valsartan"],
            "severity": "low",
            "mechanism": "Duplicate ARB therapy",
            "clinical_effect": "No benefit, increased risk",
            "penalty": -3,
            "management": "Use only one ARB",
            "evidence_level": "High",
            "source": "Hypertension guidelines"
        },
        {
            "id": "ddi_044",
            "drug_pair": ["lisinopril", "losartan"],
            "severity": "medium",
            "mechanism": "Dual RAAS blockade (ACE inhibitor + ARB)",
            "clinical_effect": "Hyperkalemia, hypotension, AKI - no mortality benefit",
            "penalty": -5,
            "management": "Generally avoid; not recommended per ONTARGET trial",
            "evidence_level": "High",
            "source": "ONTARGET trial, FDA advisory"
        },
        {
            "id": "ddi_045",
            "drug_pair": ["enalapril", "valsartan"],
            "severity": "medium",
            "mechanism": "Dual RAAS blockade",
            "clinical_effect": "Increased adverse events without benefit",
            "penalty": -5,
            "management": "Contraindicated in diabetes, CKD",
            "evidence_level": "High",
            "source": "VA-NEPHRON-D trial, ESC guidelines"
        },
        {
            "id": "ddi_046",
            "drug_pair": ["metformin", "furosemide"],
            "severity": "low",
            "mechanism": "Diuretic may cause dehydration, affecting metformin clearance",
            "clinical_effect": "Slight increased metformin levels (rarely clinically significant)",
            "penalty": -2,
            "management": "Monitor renal function, ensure hydration",
            "evidence_level": "Low",
            "source": "DrugBank"
        },
        {
            "id": "ddi_047",
            "drug_pair": ["amlodipine", "atorvastatin"],
            "severity": "low",
            "mechanism": "CYP3A4 inhibition by amlodipine",
            "clinical_effect": "Increased statin levels, myopathy risk",
            "penalty": -2,
            "management": "Limit atorvastatin to â‰¤20mg daily with amlodipine",
            "evidence_level": "Medium",
            "source": "FDA Label, DrugBank"
        },
        {
            "id": "ddi_048",
            "drug_pair": ["aspirin", "lisinopril"],
            "severity": "low",
            "mechanism": "High-dose aspirin may reduce ACE inhibitor efficacy",
            "clinical_effect": "Reduced blood pressure lowering",
            "penalty": -2,
            "management": "Use low-dose aspirin (<325mg), monitor BP",
            "evidence_level": "Low",
            "source": "Clinical guidelines"
        }
    ],
    "metadata": {
        "version": "2.0.0",
        "last_updated": "2026-02-15",
        "total_interactions": 48,
        "severity_distribution": {
            "high": 15,
            "medium": 24,
            "low": 9
        },
        "sources": [
            "FDA Drug Labels",
            "DrugBank",
            "DDInter Database",
            "UpToDate",
            "Clinical Practice Guidelines (ACC/AHA, ESC, ADA)",
            "Major Clinical Trials (ONTARGET, VA-NEPHRON-D)"
        ],
        "curator": "Herald Michain Samuel Theo Ginting",
        "validation": "Cross-referenced with FDA, DrugBank, and clinical literature",
        "phase": "Phase 8 - Knowledge Base Expansion",
        "changelog": "Added 36 new DDI pairs for expanded cardiovascular drug set, prioritizing high-severity interactions (DOACs, RAAS blockers, antiplatelets, cardiac glycoside combinations)"
    }
}